Innocoll — Patent Portfolio

Verdict Innocoll's patent portfolio is moderately strong, but faces significant revenue risk in 2034 with 1 drug losing exclusivity, including Bupivacaine Hydrochloride And Epinephrine.

Portfolio overview Innocoll's patent portfolio consists of 7 drugs, with 1 drug having patents and a total of 108 US patents, all of which are active. The average vulnerability score is 64, indicating a moderate level of vulnerability. The portfolio has 0 ironclad patents and 49 vulnerable patents. There are no biologics in the portfolio.

Cliff calendar Innocoll faces significant revenue risk in 2034, with 1 drug losing exclusivity, including Bupivacaine Hydrochloride And Epinephrine. This is the only year with a notable number of drugs losing exclusivity, with a total of 1 drug.

Most exposed drugs The top drug facing near-term loss of exclusivity is Bupivacaine Hydrochloride And Epinephrine, with an earliest active patent expiry date of 2034-03-13, an average vulnerability score of 64, and no annual revenue data available. This drug has 108 patents and is the only drug in the portfolio with a notable level of vulnerability.

Biologic exclusivity There are no biologics in Innocoll's portfolio, and therefore there are no biologics with BPCIA 12-year reference product exclusivity.

Strategic implications Innocoll faces significant revenue risk in the next 5 years, with a total of $0 at risk. The company should consider lifecycle moves such as subQ switches, label extensions, and combination filings to mitigate this risk.